Trials / Completed
CompletedNCT01865799
A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 64,186 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, 3-year observational study to describe drug utilization in uninfected individuals (UIs) who initiate emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre-exposure prophylaxis (PrEP) indication. An electronic source of pharmacy/medical encounter information will be used to assess the demographics and other characteristics of the subjects prescribed FTC/TDF or its components in a prospective fashion. The data provider will supply all the de-identified information regarding each visit/interaction that the subject has had with the health system and all the diagnoses and medications that the UI has had prospectively and retrospectively for the length of time captured by the source selected. 200 physicians who prescribe FTC/TDF for a PrEP indication will be sampled from the same source.
Conditions
Timeline
- Start date
- 2013-04-22
- Primary completion
- 2018-01-22
- Completion
- 2018-01-22
- First posted
- 2013-05-31
- Last updated
- 2018-03-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01865799. Inclusion in this directory is not an endorsement.